12:00 AM
Aug 20, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Bacillus Calmette-Guerin: Phase I data

Researchers at Harvard and colleagues reported data from a double-blind, placebo-controlled, U.S. Phase I trial showing that 2 doses of a BCG vaccine led to transient increases in dead insulin autoreactive T cells - which normally attack and destroy insulin-producing pancreatic B cells in Type I diabetes - and Treg cells - which suppress the activity of autoreactive T cells. Additionally, the researchers said 1 placebo-treated patient unexpectedly developed acute Epstein-Barr virus...

Read the full 339 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >